PMID- 19369473
OWN - NLM
STAT- MEDLINE
DCOM- 20090805
LR  - 20220409
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 36
IP  - 6
DP  - 2009 Jun
TI  - Minimal clinically important difference in the fibromyalgia impact questionnaire.
PG  - 1304-11
LID - 10.3899/jrheum.081090 [doi]
AB  - OBJECTIVE: The Fibromyalgia Impact Questionnaire (FIQ) is a disease-specific 
      composite instrument that measures the effect of problems experienced by patients 
      with fibromyalgia (FM). Utilization of the FIQ in measuring changes due to 
      interventions in FM requires derivation of a clinically meaningful change for 
      that instrument. Analyses were conducted to estimate the minimal clinically 
      important difference (MCID), and to propose FIQ severity categories. METHODS: 
      Data from 3 similarly designed, 3-month placebo-controlled, clinical treatment 
      trials of pregabalin 300, 450, and 600 mg/day in patients with FM were modeled to 
      estimate the change in the mean FIQ total and stiffness items corresponding to 
      each category on the Patient Global Impression of Change. FIQ severity categories 
      were modeled and determined using established pain severity cutpoints as an 
      anchor. RESULTS: A total of 2228 patients, mean age 49 years, 93% women, with a 
      mean baseline FIQ total score of 62 were treated in the 3 studies. Estimated MCID 
      on a given measure were similar across the studies. In a pooled analysis the 
      estimated MCID (95% confidence interval) was 14% (13; 15) and for FIQ stiffness 
      it was 13% (12; 14). In the severity analysis a FIQ total score from 0 to <39 was 
      found to represent a mild effect, >or= 39 to <59 a moderate effect, and >or=59 to 
      100 a severe effect. CONCLUSION: The analysis indicates that a 14% change in the 
      FIQ total score is clinically relevant, and results of these analyses should 
      enhance the clinical utility of the FIQ in research and practice.
FAU - Bennett, Robert M
AU  - Bennett RM
AD  - Oregon Health and Science University, Portland, OR, USA.
FAU - Bushmakin, Andrew G
AU  - Bushmakin AG
FAU - Cappelleri, Joseph C
AU  - Cappelleri JC
FAU - Zlateva, Gergana
AU  - Zlateva G
FAU - Sadosky, Alesia B
AU  - Sadosky AB
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090415
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Analgesics)
RN  - 55JG375S6M (Pregabalin)
RN  - 56-12-2 (gamma-Aminobutyric Acid)
SB  - IM
MH  - Analgesics/therapeutic use
MH  - *Disability Evaluation
MH  - Female
MH  - Fibromyalgia/complications/drug therapy/*physiopathology
MH  - *Health Status
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pain/drug therapy/etiology/physiopathology
MH  - Pregabalin
MH  - Randomized Controlled Trials as Topic
MH  - *Severity of Illness Index
MH  - Sickness Impact Profile
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
MH  - gamma-Aminobutyric Acid/analogs & derivatives/therapeutic use
EDAT- 2009/04/17 09:00
MHDA- 2009/08/06 09:00
CRDT- 2009/04/17 09:00
PHST- 2009/04/17 09:00 [entrez]
PHST- 2009/04/17 09:00 [pubmed]
PHST- 2009/08/06 09:00 [medline]
AID - jrheum.081090 [pii]
AID - 10.3899/jrheum.081090 [doi]
PST - ppublish
SO  - J Rheumatol. 2009 Jun;36(6):1304-11. doi: 10.3899/jrheum.081090. Epub 2009 Apr 
      15.